Trial · NCT07261215
Zuberitamab for EBV Infection Post-Allo-HSCT
NCT07261215, Phase 2, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Zuberitamab for EBV Infection Post-Allo-HSCT. Trials, record NCT07261215. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07261215
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Zuberitamab for EBV Infection Post-Allo-HSCT
- NCT number
- NCT07261215
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- HSCT, EBV Infection
- Interventions
- Zuberitamab
- First posted
- 2025-12-03
- Last updated
- 2025-12-03
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | EBV-DNA clearance rate | 28 days after treatment | |
| Secondary | overall survival (OS) | 180days | |
| Secondary | relapse-free survival (RFS) | 180 days | |
| Secondary | Treatment-related mortality | 180 days | |
| Secondary | Incidence of post-transplant lymphoproliferative disease (PTLD) | 180 days | |
| Secondary | Incidence of hemophagocytic syndrome | 180 days | |
| Secondary | Infection rates | 180 days | |
| Secondary | use of second-line therapy of anti-EBV | 180 days | |
| Secondary | AE | 180 days | incidence of adverse events as assessed by the NCI CTCAE version 5.0 criteria |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07261215
GET https://conductscience.org/api/trials/v1/NCT07261215/registered